Important advances have occurred during these last years on the understanding of the signaling, metabolic, epigenetic, and genetic changes that occur in tumor cells. In addition, better views have been obtained on the sociobiology of the cancer cell in relation to its surrounding transformed counterparts, stromal cells, and immune cells. These advances have translated into a holistic view of the main biological processes that are important for the development of the tumorigenic phenotype. As a result, we are now in an excellent condition to apply these advances in issues of clinical interest, such as the development of better diagnostic and prognostic tools and, for the first time in the history of biomedicine, the design of new anti-tumoral therapies aiming at blocking specific molecular targets of cancer cells. In this context, this workshop is intended to provide a format for the exchange of ideas and information, to discuss the latest research findings and methodological advances, and to foster interactions amongst groups active in diverse systems related to the molecular biology and pathophysiology of the cancer cell. Special topics of attention will be those related to the discussion of the different signal transduction pathways that contribute to the malignancy of the cancer cell, the manipulation of the metabolome by cancer cells, the processes of senescence and genetic instability, and the cell-cell relationships that are established during tumor progression among malignant cells, stromal cells and the immune system

Linda Van Aelst

Cold Spring Harbor Lab., Cold Spring Harbor, NY (USA)

Dario Alessi

University of Dundee, Dundee (UK)

Frances Balkwill

Institute of Cancer Res., London (UK)

Dafna Bar-Sagi

New York Univ., New York, NY (USA)

Johaness L. Bos

Univ. Medi. Cent., Utrecht (The Netherlands)

Xosé R. Bustelo

Centro Inv. del Cancer, Salamanca (Spain)

Judith Campisi

Lawrence Berkeley Lab., Berkeley, CA (USA)

Navdeep S. Chandel

Northwestern Univ., Chicago, IL (USA)

Sankar Ghosh

Yale University, New Haven, CT (USA)

Amato J. Giaccia

Stanford University, Stanford, CA (USA)

Eyal Gottlieb

Cancer Research UK, Glasgow (UK)

Douglas R. Green

St. Jude Chidren’s Hosp., Menphis, TN (USA)

Jan H. J. Hoeijmakers

Erasmus Med. Cent., Rotterdam (The Netherlands)

Guillermina Lozano

Univesity of Texas, Huston, TX (USA)

Tak W. Mak

Princess Margaret Hosp., Toronto, ON (Canada)

Chris Marshall

Institute of Cancer Res., London (UK)

Gerry Melino

University of Tor Vergata, Rome (Italy)

Jorge Moscat

Univ. of Cincinnati, Cincinnati, OH (USA)

Benjamin Neel

B. I. D. Medical Center, Boston, MA (USA)

Pier Giuseppe Pelicci

European Inst. of Oncology, Milan (Italy)

Jeffrey W. Pollard

Albert Einstein College of Medicine, New York NY (USA)

David M. Sabatini

Whitehead Institute, Cambridge, MA (USA)

M. Celeste Simon

Univ. of Pennsylvania, Philadelphia, PA (USA)

Bing Su

Yale School of Medicine, New Haven, CT (USA)

Jenny Ting

Univ. of North Carolina, Chapel Hill, NC (USA)